

## LncRNA Sequencing

Long non-coding RNAs (lncRNAs) are defined as  $\geq 200$  nucleotide long RNAs, which regulate gene expression at epigenetic, transcriptional, and post-transcriptional levels through binding to DNA, RNA, or protein.

In this post-genomic era, lncRNAs are gaining increasing attention in areas of medical and agricultural research.

### Our Key Features & Advantages



#### Directional Library

We offer directional library after rRNA removal, adding information on the originating strand of transcripts.



#### Comprehensive Integrated Analysis

Comprehensive integrated analysis of lncRNA and mRNA with one library construction.



#### Reliable & Faster Turnaround Time

The strategic locations of our labs across Asia and our extensive NGS system can provide faster turnaround time.



#### Extensive Experience


We have extensive records of sequencing projects that have been published in journals.




#### Unsurpassed Data Quality

We guarantee that  $\geq 80\%$  of bases have a sequencing quality score  $\geq Q30$ , exceeding Illumina's official guarantee of  $\geq 75\%$ .

### Project Workflow



## Standard Analysis Pipeline



## Sample Requirements

Library Type	Sample Type	Amount	Volume	Concentration	RIN	Purity (Nanodrop/Agarose Gel)
lncRNA Library (250-300bp insert directional library with rRNA removal)	Total RNA	≥ 0.5 µg	≥ 20 µL	≥ 50 µL	Animal ≥ 6.5 Plant/Fungi ≥ 6, with the smooth baseline	OD260/280 ≥ 2.0 OD260/230 ≥ 2.0; no degradation, no contamination
Exosomal lncRNA Library	Exosome Total RNA	≥ 5 ng	≥ 10 µL	-	Fragments distributing between 25-200nt (by high sensitive Agilent Bioanalyzer 2100), FU>10, with no peak>2000nt	

## Publications

Journal	IF	Title
Molecular Cancer	10.68	A novel IFN $\alpha$ -induced long non-coding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma (2020.01)
Nature Genetics	25.46	Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression (2018.06)

### NovogeneAIT Genomics Singapore Pte. Ltd.

(Regional office for Asia Pacific, Middle-East & Africa)

[novogene.com/amea-en](http://novogene.com/amea-en)    [marketing\\_amea@novogeneait.sg](mailto:marketing_amea@novogeneait.sg)

[NovogeneAIT](#)    [NovogeneAMEA](#)

© 2023 Novogene Co., Ltd. All Rights Reserved.

Information and specifications are subject to change at any time without notice.

Please contact your Novogene representative.

AMEA.lncRNAflyerv4.20220322